š§¬ This Week in Gene & Cell Therapy: Sarepta Elevidys Resumes, Roche Faces Setback, Mayo Clinic Breakthrough
From Sareptaās resumed shipments of Elevidys to Mayo Clinicās progress in gene therapy for osteoarthritis, this week’s episode dives into the latest advances in gene and cell therapy. Whether youāre following the impact of Duchenne treatments or tracking breakthroughs in rare diseases, this episode covers the pivotal moments you need to know! š¬š”
š Highlights in this episode:
āļø Sarepta Resumes Elevidys Shipments after FDA lifts pause for ambulatory Duchenne muscular dystrophy patients
šŖšŗ Roche Faces Setback in the EU with Elevidys as the EMA issues a negative opinion for approval in ambulatory Duchenne patients
š§¬ Genethon Launches Phase 3 Trial for GNT0004, a microdystrophin gene therapy for Duchenne muscular dystrophy
š” Mayo Clinicās Progress in gene therapy for osteoarthritis showing long-lasting pain relief and joint function improvements
ā¤ļøāš©¹ Rocket Pharmaceuticals Restructures to focus on cardiovascular gene therapies while reducing its workforce
š§āš¬ AscellaHealth Supports Launch of ZEVASKYN, a gene therapy for recessive dystrophic epidermolysis bullosa
šļø Diorasis Partners for Glaucoma Gene Therapy development to bring long-lasting efficacy with a single dose
š Adaptimmune Sells Cell Therapies amid financial restructuring as it focuses on streamlining operations
š« AstraZeneca Drops Neogeneās Lead Cancer Treatment following disappointing Phase 1 results
š¬ Elpis Biopharmaceuticals Partners with NCCS to advance CAR-T therapies for solid tumors
This isnāt just a news recapāitās your go-to pulse check on the science reshaping tomorrowās medicine. šÆ
š¢ Stay Ahead in Gene and Cell Therapy Research!
ā
Like, share, and subscribe for weekly updates on gene therapy, cell therapy, rare diseases, and biotech innovation
#GeneTherapy #CellTherapy #DuchenneMuscularDystrophy #OsteoarthritisTreatment #CardiovascularTherapies #BiotechNews #GeneTherapyBreakthroughs #LucidQuest #LQVentures #ClinicalTrials #RareDiseaseInnovation #FDAUpdates #BiotechInnovation